Purpose To develop evidence-based guidelines, based on a systematic review, for
endocrine therapy for postmenopausal women with hormone receptor–positive breast …

The experience of pain in cancer is widely accepted as a major threat to quality of life, and
the relief of pain has emerged as a priority in oncology care. Pain is associated with both the …

Purpose Arthralgia occurs in up to 50% of breast cancer survivors treated with aromatase
inhibitors (AIs) and is the most common reason for poor AI adherence. We conducted, in 121 …

Purpose Aromatase inhibitors (AIs) are effective for treatment of hormone receptor–positive
breast cancer, but adherence and persistence with therapy are poor. Predictors of treatment …

Overweight and obesity are risk factors for postmenopausal breast cancer, and many
women diagnosed with breast cancer, irrespective of menopausal status, gain weight after …

Though aromatase inhibitors (AIs) are an essential part of estrogen receptor-positive (ER+)
breast cancer therapy, many patients discontinue the medicine before their adjuvant therapy …

The association of female sex with certain rheumatic symptoms and diseases is now
indisputable. Some of the most striking examples of this association occur in individuals with …

Aromatase inhibitors (AIs) are a key component in the chemoprevention and treatment of
hormone receptor-positive (HR+) breast cancer. While the addition of AI therapy has …

Background Although aromatase inhibitors have proven to be an effective treatment of
hormone receptor-positive breast cancer in postmenopausal women, aromatase inhibitor …

Introduction and aims To provide a current perspective on nutrition and physical activity
influence on breast cancer. Methods and results A comprehensive literature review was …